Company intelligence / Profile preview

acis Arzneimittel

Oberhaching, Bavaria, Germany

Ownership: Private
Development stage: Other

Overview

acis Arzneimittel develops and sells commercialized generic pharmaceuticals, with a current portfolio covering at least 34 active ingredients used to treat conditions like allergies, Parkinson's disease, and more; products are in routine clinical use.

Therapeutic areas: ImmunologyEndocrinologyInfectious DiseasesOtherNeurology
Modalities: Small moleculeBiologic
Industry: Biotech

Partnerships

Part of Dermapharm Group, which collaborates with companies like Hasan-Dermapharm and other subsidiaries for manufacturing and distribution

Beyond the preview

Go deeper on acis Arzneimittel.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on acis Arzneimittel.

Explore the full profile